TAMH
VRNA

Taikang Asset Management (HK)’s Verona Pharma VRNA Stock Holding History

Taikang Asset Management (HK)’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50,000
Closed -$1.44M – 117
2024
Q3 		$1.44M Hold
50,000
– – 0.15% 92
2024
Q2 		$723K Buy
+50,000
New +$730K 0.11% 89

Other funds holding VRNA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Taikang Asset Management (HK)'s VRNA Position: Q4 2024 in Review

Taikang Asset Management (HK) sold out of Verona Pharma (VRNA) in Q4 2024, closing a stake of 50,000 shares — an estimated $1.44M sold.

Taikang Asset Management (HK) first reported a position in VRNA in Q2 2024 and held it in 2 quarters. The position peaked at $1.44M in Q3 2024. 191 funds tracked by Wall St. Rank hold VRNA as of Q4 2024.

  • Taikang Asset Management (HK) reported no remaining Verona Pharma position as of Q4 2024 after selling out during the quarter.
  • Taikang Asset Management (HK) sold 50,000 Verona Pharma shares in Q4 2024, an estimated $1.44M.
  • Taikang Asset Management (HK) first reported a position in Verona Pharma in Q2 2024 and held it in 2 quarters.
  • Taikang Asset Management (HK)'s Verona Pharma position peaked at $1.44M in Q3 2024.
  • 191 funds tracked by Wall St. Rank held Verona Pharma as of Q4 2024.

Based on Taikang Asset Management (HK)'s 13F filing for Q4 2024, filed 11 Feb 2025.